Hi-Risk/Recurrent/Advanced PCa Video Chat, Feb 27, 2024
AnCan is grateful to the following sponsors for making this recording possible: Bayer, Foundation Medicine, Janssen, Myriad Genetics, Myovant, Telix & Blue Earth Diagnostics.
In a special session before tonight’s meeting, we presented key papers from ASCO GU 2024, a major conference for doctors treating prostate cancer, and answered questions — details here.
AnCan respectfully notes that it does not accept sponsored promotion. Any drugs, protocols or devices recommended in our discussions are based solely on anecdotal peer experience or clinical evidence.
AnCan cannot and does not provide medical advice. We encourage you to discuss anything you hear in our sessions with your own medical team.
AnCan reminds all Participants that Adverse Events experienced from prescribed drugs or protocols should be reported to the pharmaceutical manufacturer or the FDA Adverse Event Reporting System (FAERS). To do so call 1-800-332-1066 or download interactive FDA Form 3500 https://www.fda.gov/media/76299/download
AnCan’s Prostate Cancer Forum is back (https://ancan.org/forums). If you’d like to comment on anything you see in our Recordings or read in our Reminders, just sign up and go right ahead. You can also click on the Forum icon at the top right of the webpage.
All AnCan’s groups are free and drop-in … join us in person sometime! You can find out more about our 12 monthly prostate cancer meetings at https://ancan.org/prostate-cancer/ Sign up to receive a weekly Reminder/Newsletter for this Group or others at https://ancan.org/contact-us/
Editor’s Pick: PSA rising but nothing on the PET scan – the tumor was hiding behind his bladder. (bn)
Topics Discussed
After beating back his cancer many times, he’s now neuroendocrine and wonders about options besides platinum (immuno, DLL3, alpha) — Dr. Rahul Aggarwal is likely to have answers; Tylenol on top of Orgovyx and darolutamide may have been one too drug too much for his liver; struggling to work remotely with Dr. E’s office team — you’ll need “a heavy dose of patience”; after 6 unhelpful chemo rounds, now seeing a good lutetium response, but unresponding tumors may be neuroendocrine; maximum out-of-pocket expense is the important number in choosing a Medicare Part D plan; trusting a broker for Medicare selection, and are Advantage plans a bad deal for cancer patients?; despite rising PSA, PSMA scan looked clear…turned out the tumor was hiding behind the bladder; good feedback on Dr. Elisabeth Heath; 90-day Lupron break to “catch my breath” — is restarting now a lost cause?; Lupron finally over, he’s switching back to a real bike from his e-bike…but when do the hot flashes stop?
Chat Log
Jim Marshall, Alexandria, VA · 5:34 PM
we all need to be our own best advocate at all times
Jim Marshall, Alexandria, VA · 6:05 PM
on a Macbook, I see all the names. without hovering
Len Sierra · 7:05 PM
Chromogranin A (CGA) and neuron-specific enolase (NSE) levels are biomarkers for NEPC. Also, synaptophysin and DLL3 (Delta-like Ligand 3) is positive in 76% of NEPC.
AnCan – rick · 7:06 PM
Contact: Garrett Crook 424-314-0745 Garrett.Crook@cshs.org Principal Investigator: Kanya Sankar, MD
AnCan – rick · 7:07 PM
DLL3 NCT04471727 https://classic.clinicaltrials.gov/ct2/show/NCT04471727?term=HPN328&cond=Prostate+Cancer&draw=2&rank=1
AnCan – rick · 7:14 PM
HPN328 is the DLL3 drug
AnCan – rick · 7:38 PM
Solo Arts Heal TOMORROW NIGHT rd + MARK KISSIN FRCS check https://ancan.org/solo-arts-heal/ for links to The Marsh page and join us on Zoom or YouTube
Thomas Matica · 7:54 PM
Did Rick say that there is video discussion on the insurance issues? I can’t find anything. Thanks.
AnCan – rick · 7:55 PM
Tom – search for Triage Cancer on our site
AnCan – rick · 7:56 PM
Here you go….. https://ancan.org/webinar-lets-talk-medicare-2024/
Patient Highlights from the 2024 ASCO GU conference
In a 75-minute “pre-game” before the 2/27/2024 meeting of the high-risk/recurrent/advanced prostate cancer group, moderators John, Rick, Ben, and Len discussed highlights from the just-concluded ASCO GU conference, a major meeting for genitourinary cancer specialists. They selected from hundreds of papers on prostate cancer presented in sessions and posters. We closed with a 30-minute audience Q&A.
What we covered:
Abi boosts olaparaib for BRCA
After triplet therapy, what next?
Less treatment, same cancer-fighting power
Trial of a neuroendocrine PCa drug
Prostate cancer and suicide
Germline & somatic testing is too infrequent
What treatments work after Pluvicto
Pluvicto flare largely lasts only one treatment
Community providers do poor job treating mCSPC men
Hi-Risk/Recurrent/Advanced PCa Video Chat, Feb 5, 2024
AnCan is grateful to the following sponsors for making this recording possible: Bayer, Foundation Medicine, Janssen, Myriad Genetics, Myovant, Telix & Blue Earth Diagnostics.
AnCan respectfully notes that it does not accept sponsored promotion. Any drugs, protocols or devices recommended in our discussions are based solely on anecdotal peer experience or clinical evidence.
AnCan cannot and does not provide medical advice. We encourage you to discuss anything you hear in our sessions with your own medical team.
AnCan reminds all Participants that Adverse Events experienced from prescribed drugs or protocols should be reported to the pharmaceutical manufacturer or the FDA Adverse Event Reporting System (FAERS). To do so call 1-800-332-1066 or download interactive FDA Form 3500 https://www.fda.gov/media/76299/download
AnCan’s Prostate Cancer Forum is back (https://ancan.org/forums). If you’d like to comment on anything you see in our Recordings or read in our Reminders, just sign up and go right ahead. You can also click on the Forum icon at the top right of the webpage.
All AnCan’s groups are free and drop-in … join us in person sometime! You can find out more about our 12 monthly prostate cancer meetings at https://ancan.org/prostate-cancer/ Sign up to receive a weekly Reminder/Newsletter for this Group or others at https://ancan.org/contact-us/
Join our other free and drop in groups: Men (Only) Speaking Freely…1st & 3rd Thursdays @ 8.00 pm Eastern https://ancan.org/men-speaking-freely/ Veterans Healthcare Navigation… 4th Thursday @ 8.00 pm Eastern https://ancan.org/veterans/
Are eye issues related to hormone therapy?; Orgovyx AND Lupron vs Orgovyx OR Lupron?; Pluvicto may be in his future; time for PSMA scan and possible end to 6 yrs HT free; exercise guidance; awaiting PSA; next steps post chemo; monotherapy darolutamide; somatic testing; bulging disc gets in the way of exercise
Webinar: Radionuclide Diagnostics & Theranostics – Theory and Clinical Practice Meet!
Nuclear payloads, guided missiles, directed assassinations…not in global conflict or wars, but prostate cancer and what happens inside bodies of men getting radionuclide theranostics (treatment) and diagnostics (scanning) today.
Radionuclide treatment for prostate cancer is at least 10 years old – does that surprise you? Bayer’s Xofigo was approved in 2013 but adoption has been slow until recent FDA approvals of theranostics (treatment) viz. Pluvicto, and diagnostics (scans) like Illucix and Posluma.
Radionuclides are theory-intense with nuclear medicine doctors less exposed to treatment of advanced prostate cancer. Conversely, GU medical oncologists are less familiar with radionuclides than hormone and chemo-therapy.
Two global experts, GU medical oncologist Dr. Oliver Sartor and nuclear medicine guru, Dr. Philip Kuo will introduce radionuclide theranostics and diagnostics and discuss how the clinic and the theory intersect.
Learn about radionuclide medicine – how it works and what it can do for you! This information will help patients learn how to make sure your Genitourinary Medical Oncologist and Nuclear Medicine Doctor work in harmony.
Watch here:
Special thanks to our sponsors who made this webinar possible….
Hi-Risk/Recurrent/Advanced PCa Video Chat, Jan 15, 2024
AnCan is grateful to the following sponsors for making this recording possible: Bayer, Foundation Medicine, Janssen, Myriad Genetics, Myovant, Telix & Blue Earth Diagnostics.
Welcome AnCan’s first 2024 webinar with two blockbuster headliners — GU med onc Dr. Oliver Sartor and nuclear medicine pioneer Dr. Phillip H. Kuo — “Radionuclide Diagnostics & Theranostics – Theory and Clinical Practice Meet!” Register now at https://tinyurl.com/radionuclide – free as always. Two globally recognized experts introduce us to radionuclide scans and treatment, and help us understand how best to coordinate our care team.
AnCan respectfully notes that it does not accept sponsored promotion. Any drugs, protocols or devices recommended in our discussions are based solely on anecdotal peer experience or clinical evidence.
AnCan cannot and does not provide medical advice. We encourage you to discuss anything you hear in our sessions with your own medical team.
AnCan reminds all Participants that Adverse Events experienced from prescribed drugs or protocols should be reported to the pharmaceutical manufacturer or the FDA Adverse Event Reporting System (FAERS). To do so call 1-800-332-1066 or download interactive FDA Form 3500 https://www.fda.gov/media/76299/download
AnCan’s Prostate Cancer Forum is back (https://ancan.org/forums). If you’d like to comment on anything you see in our Recordings or read in our Reminders, just sign up and go right ahead. You can also click on the Forum icon at the top right of the webpage.
All AnCan’s groups are free and drop-in … join us in person sometime! You can find out more about our 12 monthly prostate cancer meetings at https://ancan.org/prostate-cancer/ Sign up to receive a weekly Reminder/Newsletter for this Group or others at https://ancan.org/contact-us/
Editor’s Pick: Four new men give us plenty to talk about. (bn)
Topics Discussed
With “innumerable” metastases, he braces for chemotherapy; urologist blames the patient for ADT mood swings, and also fails to prescribe second-line drug; focal therapy might be right for post-radiation recurrence; PSA nearly 50 but biopsy claims he’s Gleason 6 — prostatectomy proves otherwise; colon cancer’s genetic tie-in with prostate cancer; drug holiday’s an option, but keep calm when PSA creeps up; “I’ve been to the four corners of the United States” seeing doctors — Dr. E is next; don’t put off somatic testing, and consider abiraterone monotherapy; let precision medicine target your BRCA before considering a clinical trial; vomiting worsens with with each Pluvicto round — seek palliative care!; wobbly testosterone recovery; even without testosterone, getting stronger through exercise.
Chat Log
Peter Kafka – Maui · 8:23 PM
somatic genetic testing
AnCan – rick · 8:28 PM
Men Speaking Freely https://ancan.org/men-speaking-freely/ Thursday, 8.00 pm Eastern in this room. Just drop-in
AnCan – rick · 8:37 PM
Genitourinary Medical Oncologist
Peter Kafka – Maui · 8:39 PM
peterk@ancan.org
AnCan – rick · 8:46 PM
Channing Paller https://www.hopkinsmedicine.org/profiles/results/directory/profile/3138167/channing-paller
AnCan – rick · 8:50 PM
PROMISE https://www.prostatecancerpromise.org/?utm_campaign=ANCAN&utm_medium=link&utm_source=Webinar
AnCan – rick · 8:54 PM
Steven don’t forget Men Speaking Freely on Thursday
dennis NJ · 9:10 PM
Thank you everyone
AnCan – rick · 9:17 PM
Elisabeth Heath https://www.karmanos.org/karmanos/karmanos-physician-directory/heath-elisabeth-8225
Frank Fabish Columbus OH · 9:39 PM
Thanks everyone. got to go.
Gary – New Jersey · 9:41 PM
Thank you everyone for the discussion and your suggestions. Have to go now.
“Thomas” Matica WA · 9:52 PM
Thanks, Len. I’ll look it up.
Len Sierra · 9:54 PM
HK2 : Human kallikrein-related peptidase 2 (hK2) is a tumor-associated member of the kallikrein family that shares significant homology to prostate-specific antigen and is minimally expressed in normal non-prostate tissues.
Jeff betz · 10:02 PM
Gotta go guys thank you!
AnCan – rick · 10:08 PM
https://ancan.org/your-dental-health/ Dental Posts
Len Sierra · 10:12 PM
Phase 2 study suggests that Abi monotherapy may be as effective as Abi + ADT. Published in journal Nature. https://www.nature.com/articles/s41391-022-00533-6
Steven Roberts · 10:13 PM
ok, fellas I got to drop….talk to you all next week and thanks
